Navigation Links
Boehringer Ingelheim's investigational volasertib receives FDA Breakthrough Therapy designation
Date:9/17/2013

RIDGEFIELD, Conn., Sept. 17, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the FDA has granted Breakthrough Therapy designation to volasertib*, an investigational inhibitor of polo-like kinase (Plk), being evaluated for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia (AML), ineligible for intensive remission induction therapy.

"This FDA Breakthrough Therapy designation provides Boehringer Ingelheim the opportunity to engage in an ongoing dialogue with the FDA  to help expedite the development of volasertib as a potential treatment option for these patients with AML," said Sabine Luik, M.D., senior vice president, Medicine & Regulatory Affairs, U.S. Regional Medical Director, Boehringer Ingelheim Pharmaceuticals, Inc. "Volasertib is one of many investigational compounds in Boehringer Ingelheim's growing oncology pipeline and is an example of our commitment to exploring treatment approaches with the goal of improving patient outcomes."

The Breakthrough Therapy designation process was established by the FDA in July 2012 and is intended to facilitate and expedite the development and review of drugs for serious or life-threatening conditions if  preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.

AML is an aggressive cancer of the bone marrow and blood.2 It accounts for 25 percent of all adult leukemias in the Western world3 and has one of the lowest survival rates of all leukemias.3 In 2013, it is estimated there will be 14,590 new cases of AML diagnosed in the U.S. and 10,370 deaths from the disease.4

AML is primarily a disease of later adulthood; the average age of an AML patient is 65 years.5 A common treatment approach for AML
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
2. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
3. Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
4. Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
5. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
6. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
7. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
8. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
9. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
10. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
11. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:7/10/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), a ... entered into an agreement with Merck KGaA, Darmstadt, ... in the United States and ... KGaA,s biopharmaceutical division on the development and commercialization of ... Ventana,s proprietary diagnostic assays. In alignment with Merck KGaA,s ...
(Date:7/10/2014)... 2014 Decision Resources Group finds that over ... Food and Drug Administration,s (FDA) approval of Vifor Fresenius ... was approved by the FDA in November 2013 for ... patients on dialysis. Other key findings from ... 2014 : , ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
(Date:7/13/2014)... irrigation systems are mainly utilized for agriculture in order ... maintain soil quality. The application of micro irrigation systems ... generator for manufacturers in future. The trend of utilizing ... to the adoption of micro irrigation techniques for agriculture, ... for micro irrigation systems, as they reduce the overall ...
(Date:7/13/2014)... MarketsandMarkets recently conducted a study on ... 3D rendering; Layout and Animation; Image Reconstruction]: Global ... which analyzes and studies the major market drivers, ... Eastern Europe, Middle East and Africa, Asia-Pacific and ... landscape of the 3D imaging market, providing an ...
(Date:7/13/2014)... York (PRWEB) July 13, 2014 The ... http://www.transvaginalmeshlawsuithelp.com/ ) filed against Johnson & Johnson’s ... bellwether trial, which is expected to get underway next ... in the U.S. District Court, Southern District of West ... be held on August 7, 2014 at 3:00 p.m. ...
(Date:7/13/2014)... Texas (PRWEB) July 13, 2014 Epidemiologists ... aGVHD in the 6MM, from 8,062 diagnosed incident cases ... at an Annual Growth Rate (AGR) of 4.35%, during ... the highest number of diagnosed incident cases of aGVHD ... Spain will have the lowest number of diagnosed incident ...
(Date:7/13/2014)... Columbus, OH (PRWEB) July 13, 2014 ... by Wright & Schulte LLC to provide consumers with ... can sometimes accompany use of the blood-thinning medication, as ... lawsuits pending in courts around the country. The ... anyone who may have suffered from life-threatening internal bleeding ...
Breaking Medicine News(10 mins):Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4
... stigma is powerful, pervasive and destructive," said Marlene Schwartz, a ... reactions to two prom photos.// , One showed a ... woman. The other was the same photo altered to show ... ,The volunteers took a quick look at one or ...
... may be much more likely to have asthma and a nighttime ... from Australia.// ,Doctors often use night cough as a guide ... the August issue of Chest, suggest it may be appropriate to ... ,"Night cough is often taken as a sign of the onset ...
... for cancer complain of feeling weak //and tried, and ... symptoms. A new study suggests that may not be ... with worse prognosis after radiotherapy, the doctors assumed the ... of the therapy, as well., ,Not so, report ...
... New research shows the same drugs you take to ... ,Researchers from the University of Pittsburgh followed more than ... than seven years. Results of the study show more ... cholesterol-lowering drugs developed breast cancer, while 2.1 percent of ...
... proved exercise reduces the risk of breast cancer, and now ... may lower a woman’s risk of developing breast carcinoma in ... into invasive breast cancer if left untreated. ,Researchers from ... 35 and 64 years old. More than 550 participants had ...
... Lung cancer is by far the biggest cancer killer around the ... survey researchers found that 38 percent of 626 patients they ... 61 percent of the black and 29 percent of the white ... air would cause it to spread., Most of the patients were ...
Cached Medicine News:Health News:False beliefs could cost cancer patients their lives 2
... Discovery 90SE Ultracentrifuge offers ... discover more. All the ... top-of-the-line performance, powerful functionality, ... use, all built into ...
... centrifuge continues to raise the standard for ... 1,048,000 x g performance and our new ... sample sizes from 0.2 ml to 8.3 ... direct drive, very quiet operation, rotor imbalance ...
... and environmental safety are the ... K Ultracentrifuge from Beckman Coulter. ... centrifugation technology, the LE-80 K ... provide advanced capability for your ...
... Capable of generating 694,000 ... to 90,000 rpm, Beckman Coulter's ... to perform more separations in ... model operates with a broad ...
Medicine Products: